[1] OSMAN A E G, DEININGER M W. Chronic myeloid leukemia: modern therapies, current challenges and future directions [J]. Blood Rev, 2021, 49: 100825.
[2] VAN KOOTEN NIEKERK P B, ROUG A S, PETERSEN C C, et al. Chronic myeloid leukaemia presenting with isolated thrombocythaemia, a case revealing its stem cell biology [J]. Br J Haematol, 2013, 162(1):141-144.
[3] MICHIELS J J, BERNEMAN Z, SCHROYENS W, et al. Philadelphia(Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia [J]. Ann Hematol, 2004, 83(8): 504-512.
[4] FADILAH S A, CHEONG S K. BCR-ABL positive essential thrombocythaemia: a variant of chronic myelogerous leukaemia or a distinct clinical entity: a special case report [J]. Singapore Med J, 2000, 41(12): 595-598.
[5] 彭树弈, 梁晔,罗琳,等. 仅以血小板增多为首发表现的慢性粒细胞白血病5例临床分析[J]. 临床血液学杂志, 2015, 28(5):757-759.
[6] 李文华. 血小板参数与骨髓病态巨核细胞在原发性血小板增多症与继发性血小板增多症鉴别诊断中的意义[J]. 中国实用医药, 2019, 14(5):14-16.
[7] SWERDLOW S H, CAMPO E, HARRIS N L, et al. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. Lyon: IARC, 2008. |
